Basic Information
| LncRNA/CircRNA Name | SNHG16 |
| Synonyms | NA |
| Region | GRCh38_17:76557766-76565348 |
| Ensemble | ENSG00000163597 |
| Refseq | NR_038108 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, qPCR, Western blot, Luciferase reporter assay, RIP |
| Sample | HepG2 and Huh-7 cell lines, normal liver cells (HL-7702), QGY-7703, SMMC-7721, HCC and normal tissues. |
| Expression Pattern | up-regulated |
| Function Description | LncRNA SNHG16 is upregulated in HCC and correlates with poorer prognosis. Patients with high SNHG16 expression showed lower rates of overall and disease-free survival than patients with low SNHG16 expression. Multivariate Cox regression revealed that SNHG16 expression was an independent predictor of poor overall and disease-free survival. In vitro, SNHG16 promoted HCC cell proliferation, migration, and invasion while inhibiting apoptosis; in vivo, it accelerated tumor development. Altering SNHG16 expression altered levels of miR-17-5p, which in turn modified expression of p62, which has been shown to regulate the mTOR and NF-?B pathways. Indeed, altering SNHG16 expression in HCC cells activated mTOR and NF-?B signaling. |
| Pubmed ID | 31256427 |
| Year | 2019 |
| Title | The lncRNA SNHG16 affects prognosis in hepatocellular carcinoma by regulating p62 expression |
External Links
| Links for SNHG16 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |